These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32518098)

  • 61. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
    Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
    J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
    Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
    Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.
    Li Y; Lupo JM; Parvataneni R; Lamborn KR; Cha S; Chang SM; Nelson SJ
    Neuro Oncol; 2013 May; 15(5):607-17. PubMed ID: 23393206
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
    Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
    Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review.
    Pirozzi M; Caterino M; Facchini S; Zotta A; Messina G; Rauso R; Sica A; Sciano D; Facchini G; Orditura M; Somma T; Maiuri F; Cappabianca P; Ciardiello F; Fasano M
    Case Rep Oncol; 2022; 15(2):642-647. PubMed ID: 35949909
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
    Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
    Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
    [TBL] [Abstract][Full Text] [Related]  

  • 73. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
    Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
    Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
    Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
    Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.
    Brodowicz T; Mir O; Wallet J; Italiano A; Blay JY; Bertucci F; Eisterer W; Chevreau C; Piperno-Neumann S; Bompas E; Ryckewaert T; Liegl-Antzwager B; Thery J; Penel N; Le Cesne A; Le Deley MC
    Eur J Cancer; 2018 Aug; 99():28-36. PubMed ID: 29902612
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages.
    Li G; Zhai Y; Wang Z; Wang Z; Huang R; Jiang H; Li R; Feng Y; Chang Y; Jiang T; Zhang W
    Cancer Med; 2020 Mar; 9(6):1955-1965. PubMed ID: 31851783
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
    Adenis A; Mazard T; Fraisse J; Chalbos P; Pastor B; Evesque L; Ghiringhelli F; Mollevi C; Delaine S; Ychou M
    BMC Cancer; 2021 May; 21(1):564. PubMed ID: 34001059
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
    Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme.
    Brzozowska A; Toruń A; Mazurkiewicz M
    Adv Clin Exp Med; 2015; 24(2):279-87. PubMed ID: 25931361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.